Research and Markets: Egypt Pharmaceuticals and Healthcare Report Q1 2012: Drastic Shortage in Affordable Medicines

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/660827/egypt_pharmaceutic) has announced the addition of the "Egypt Pharmaceuticals and Healthcare Report Q1 2012" report to their offering.

“Egypt Pharmaceuticals and Healthcare Report Q1 2012”

Egypt's pharmaceutical and healthcare market has not been fundamentally changed by the political upheaval. The country still has a large population, an emerging middle class and should continue to grow rapidly economically, provided it does not become too destabilised by political infighting and fiscal overspending by the next government. That said, risks remain high and the country's drug pricing and regulatory regime is in need of overhaul.

Headline Expenditure Projections

• Pharmaceuticals: EGP16.69bn (US$2.96bn) in 2010 to EGP17.37bn (US$2.92bn) in 2011; +4.1% in local currency terms and -1.4% in US dollar terms. Forecast up slightly from Q411 due to new data. Growth forecast down slightly because of medicine shortages.
• Healthcare: EGP60.39bn (US$10.72bn) in 2010 to EGP65.43bn (US$10.99bn) in 2011; +8.3% in local currency terms and +2.8% in US dollar terms. Forecast down significantly from Q411 due to new historic data.
• Medical devices: EGP2.78bn (US$493mn) in 2010 to EGP3.02bn (US$508mn) in 2011; +8.7% in local currency terms and +2.9% in US dollar terms. Forecast down slightly from Q411 due to macroeconomic factors.

Key Trends And Developments

• A report by the Egyptian Ministry of Finance said the government will try to encourage investment in the healthcare sector and it has assigned EGP10bn (US$1.67bn) for healthcare investment in its FY2011/12 budget.
• Egypt is experiencing a drastic shortage in affordable medicines according to the UN's Office for the Coordination of Humanitarian Affairs.

Key Topics Covered:

• SWOT Analysis
• Regulatory Regime
• Intellectual Property Developments
• Counterfeit Medicines
• Free Trade Agreements
• Pricing Regime
• Industry Developments
• Epidemiology
• Communicable Diseases
• Healthcare Sector
• Research And Development Activity
• Clinical Trials
• Medical Devices
• Industry Forecast Scenario
• Competitive Landscape
• Retail Pharmacies
• Herbal And OTC Medicine

Companies Mentioned:

• Egyptian International Pharmaceutical Industries Co (EIPICO)
• South Egyptian Drug Industries (SEDICO)
• Alexandria Pharmaceuticals
• Amoun Pharmaceutical Company (APC)
• VASCERA
• Misr Pharmaceuticals
• GlaxoSmithKline (GSK)
• Sanofi-Aventis
• Pfizer
• Novartis
• Merck & Co
• AstraZeneca

For more information visit http://www.researchandmarkets.com/research/660827/egypt_pharmaceutic